The latest review presents TAM-based drugs used in CRC immunotherapy as follows: CET [200], Maraviroc (CCR5 inhibitor) [201], or regorafenib (REG) (tyrosine kinase inhibitor) [202] (reviewed in [157]). The gene discussed is CCR5; the disease is colorectal carcinoma.